The value of any intervention for multiple myeloma (MM) must be expressed as an equation: value equals cost plus quality of care. The simplicity of this formula, however, disguises the complexity of cost calculation and quality evaluation. To determine cost, clinicians, payers, and other stakeholders must identify both short-term and long-term utilization costs, ancillary costs for adverse events, and the cost of gains or losses in productivity associated with an intervention.
Stay up to date with the latest news in neurology by subscribing to receive the free VBCN e‑Newsletter.